The YCC internal and external advisory groups have provided invaluable guidance in planning and evaluation of all the major initiatives since the last NCI CCSG review, particularly during the last three years since the appointment of Dr. Lynch as Director. The Director has modified and improved the network of decision-making and advisory groups to include: ? The Director's Mini-Cabinet (Mini-Cab) is composed of the Director, Deputy Directors, and Associate Directors and meets weekly to evaluate progress in strategic YCC initiatives. ? The Executive Committee meets weekly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the Mini-Cab members. ? The Internal Advisory Board, comprised of three senior leaders from the Yale School of Medicine, meets periodically with the Director to review pivotal YCC activities. ? The External Scientific Advisory Board (ESAB) has been expanded with the addition of several experienced Cancer Center leaders and includes 16 members, with complementary expertise in basic, translational, and population sciences. In addition, on the advice of the ESAB we have developed and are continually refining a Strategic Plan. With careful planning and evaluation by advisory groups, the YCC has successfully initiated the Strategic Plan, the reorganization of the Research Programs and their leadership, the integration of the new Smilow Cancer Hospital, and the substantial improvements in the clinical trials infrastructure. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that the YCC can most effectively set priorities and pursue objectives that help shape of basic, clinical, prevention and translational research at Yale.

Public Health Relevance

Program Planning and Evaluation is crucial to the effective functioning and long-term strategic planning of the YCC. Input and guidance from external and internal advisory groups has encouraged the growth of the Center during the project period and will continue to develop the YCC's strengths moving forward.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications